Estrogen metabolomics: A physiologist's perspective

Hypertension

Volumn 56, Issue 5, 2010, Pages 816-818

  Miller, Virginia M ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHOXYESTRADIOL; 3 HYDROXY 3 METHYLGLUTARYL COENZYME A; CATECHOL METHYLTRANSFERASE; CHOLESTEROL; CYCLIN B1; CYCLIN D1; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; ESTRADIOL; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INTERSTITIAL COLLAGENASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PROGESTERONE; TESTOSTERONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ATHEROSCLEROSIS; CANCER CELL CULTURE; CELL DIVISION; CELL PROLIFERATION; CELL VIABILITY; CHOLESTEROL BLOOD LEVEL; DOWN REGULATION; ENZYME ACTIVITY; ESTROGEN METABOLISM; GENE EXPRESSION; GLOMERULUS FILTRATION; ISCHEMIC HEART DISEASE; KIDNEY BLOOD FLOW; METABOLOMICS; NONHUMAN; NOTE; PRIORITY JOURNAL; PROGESTERONE BLOOD LEVEL; PROTEIN EXPRESSION; SMOOTH MUSCLE FIBER; SYSTOLIC BLOOD PRESSURE; TESTOSTERONE BLOOD LEVEL; VASCULAR SMOOTH MUSCLE; ANIMAL; METABOLISM;

ANIMALS; ESTRADIOL;

EID: 78149240156     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.110.154385     Document Type: Note

References (10)

1. Zhu BT, Conney AH. Functional role of estrogen metabolism in target cells: review and perspectives. Carcinogenesis. 1998;19:1-27.
2. Barchiesi F, Lucchinetti E, Zaugg M, Ogunshola OO, Wright M, Meyer M, Rosselli M, Schaufelberger S, Gillespie DG, Jackson EK, Dubey RK. Candidate genes and mechanisms for 2-methoxyestradiol-mediated vasoprotection. Hypertension. 2010;56:964-972.
3. Mooberry SL. New insights into 2-methoxyestradiol, a promising antiangiogenic and antitumor agent. Curr Opin Oncol. 2003;15:425-430.
4. Sweeney C, Liu G, Yiannoutsos C, Kolesar J, Horvath D, Staab MJ, Fife K, Armstrong V, Treston A, Sidor C, Wilding G. A phase II multicenter, randomized, double-blind, safety trial assessing the pharmacokinetics, pharmacodynamics, and efficacy of oral 2-methoxyestradiol capsules in hormone-refractory prostate cancer. Clin Cancer Res. 2005;11:6625-6633.
5. Bourghardt J, Bergstrom G, Krettek A, Sjoberg S, Boren J, Tivesten A. The endogenous estradiol metabolite 2-methoxyestradiol reduces atherosclerotic lesion formation in female apolipoprotein e-deficient mice. Endocrinology. 2007;148:4128-4132.
6. Zhang X, Jia Y, Jackson EK, Tofovic SP. 2-Methoxyestradiol and 2-ethoxyestradiol retard the progression of renal disease in aged, obese, diabetic zsf1 rats. J Cardiovasc Pharmacol. 2007;49:56-63.
7. Nissen SE, Wolski K. Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Arch Intern Med. 2010;170:1191-1201.
8. Harman SM, Brinton EA, Cedars M, Lobo R, Manson JE, Merriam GR, Miller VM, Naftolin F, Santoro N. KEEPS: the Kronos Early Estrogen Prevention Study. Climacteric. 2005;8:3-12.
9. Tempfer CB, Riener EK, Hefler LA, Huber JC, Muendlein A. DNA microarray-based analysis of single nucleotide polymorphisms may be useful for assessing the risks and benefits of hormone therapy. Fertil Steril. 2004;82:132-137.
10. Wang S, Shi X, Chien X, Baker Jj. Therapeutic efficacy of 2-methoxyestradiol microcyyrstals encapuslated within polyelectrolyte multilayers. Macromol Biosci. 2009;9:429-436.